XBIT is the ticker symbol for XBiotech Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks XBIT with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is XBIT a good stock to buy?

XBIT is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/XBIT.

Where does 13F Pro source XBIT data?

All XBiotech Inc. fundamentals and ownership data come directly from SEC EDGAR. XBiotech Inc. files with the SEC under CIK 1626878. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

XBiotech Inc.(XBIT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

XBiotech Inc. (XBIT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. XBIT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 40 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q2 2026), XBiotech Inc. reports net income of $-6.7M, free cash flow of $-4.5M. Top institutional holders of XBIT by reported 13-F value include BlackRock, GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. XBIT trades on the Nasdaq exchange and files with the SEC under CIK 1626878. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XBIT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for XBiotech Inc. directly from SEC EDGAR.

Net Income

$-6.7M

Free Cash Flow

$-4.5M

XBIT key financials by period

XBiotech Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2022	10-K	$4.0M	$-32.9M	—
FY 2021	10-K	$18.4M	$-17.4M	-136.4%
FY 2020	10-K	$44.0M	$-11.2M	-41.5%

Institutions holding XBIT

Institutional investors reporting a position in XBiotech Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
BlackRock	321,146	$738.6K	2026-06-30
GEODE CAPITAL MANAGEMENT	214,116	$492.8K	2026-06-30
VANGUARD CAPITAL MANAGEMENT	200,182	$460.4K	2026-06-30
RBF Capital	198,501	$456.6K	2026-06-30
MORGAN STANLEY	147,880	$340.1K	2026-06-30
BRIDGEWAY CAPITAL MANAGEMENT	98,447	$226.4K	2026-06-30
VANGUARD FIDUCIARY	92,365	$212.4K	2026-06-30
MILLENNIUM MANAGEMENT	79,330	$182.5K	2026-06-30
JANE STREET GROUP	74,700	$171.8K	2026-06-30
STATE STREET	73,006	$167.9K	2026-06-30

SEC EDGAR: CIK 1626878 →

XBiotech Inc.

XBIT

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 40 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.